Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
University of Toronto · Princess Margaret Cancer Centre · +25 more institutions
Abstract
Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation. The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed. A total of 137 patients (60 with non–small-cell lung cancer [NSCLC], 55 with colorectal cancer, and 22 with other solid tumors) received divarasib. No dose-limiting toxic effects or treatment-related deaths were reported.…
Citation impact
- FWCI
- 41.05
- Percentile
- 100%
- References
- 24
Authors
27- AGAdrian G. SacherCorresponding
University of Toronto, Princess Margaret Cancer Centre, University College London
- PLPatricia LoRusso
Princess Margaret Cancer Centre, Yale Cancer Center, Yale University, University College London
- MRManish R. Patel
Princess Margaret Cancer Centre, Sarah Cannon, University College London
- WHWilson H. Miller
Jewish General Hospital, Princess Margaret Cancer Centre, University College London, McGill University
- EGElena Garralda
Hebron University, Princess Margaret Cancer Centre, University College London
Topics & keywords
- KRAS
- Medicine
- Discontinuation
- Adverse effect
- Colorectal cancer
- Internal medicine
- Gastroenterology
- Confidence interval
- Good health and well-being